Alvotech (ALVO)
NASDAQ:ALVO
Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$3.61
$0.06(0.46%)
At close: 4:00 PM EST
$3.61
$0.06(0.46%)
Day’s Range― - ―
52-Week Range$2.94 - $9.94
Previous CloseN/A
Volume41.59K
Average Volume (3M)640.03K
Market Cap
$1.30B
Enterprise Value$2.44B
Total Cash (Recent Filing)$63.83M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 19, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding312,048,280
10 Day Avg. Volume1,062,087
30 Day Avg. Volume640,034
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap1.88
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit7.11
Enterprise Value/Ebitda111.33
Forecast
1Y Price Target
$4.67Price Target Upside29.27% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.06
Revenue Forecast (FY)$622.73M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue ScaleAlvotech has materially scaled top-line revenue while maintaining gross margins around 60%, creating durable operating leverage typical of biosimilars. Strong product unit economics support reinvestment in pipeline and commercial expansion, improving long-term cash conversion as volumes ramp.
Global Commercial Partnerships & ReachA broad partner network and rapid market uptake (AVT02 achieving meaningful U.S. share and presence in 90+ countries) deliver durable market access and lower go‑to‑market execution risk. Partnered commercialization scales sales reach and supports repeatable launches across geographies.
Manufacturing DiversificationThe Fujifilm manufacturing deal diversifies capacity and establishes U.S. supply, materially reducing single‑site dependence. Adding third‑party U.S. production capacity enhances long‑term supply resilience, lowers risk of launch disruptions, and supports expansion into larger markets.
Bears Say
High Leverage & Negative EquityAlvotech's capital structure is a structural weakness: substantial debt relative to assets and persistent negative shareholders' equity reduce financial flexibility. Elevated leverage raises refinancing and interest coverage risk, limiting ability to fund launches or absorb delays without dilutive or costly financing.
Sustained Cash BurnConsistent negative operating and free cash flow indicate the business does not self‑fund current investments and commercialization. Reliance on financing or lumpy licensing milestones increases execution risk and can constrain timing of product rollouts and manufacturing scale-up over the next several quarters.
Regulatory & Throughput RiskRegulatory findings and intentional production slowdowns to address them have depressed throughput and product margins, and delayed BLA timelines. This structural operational risk can prolong time to market, keep product margins suppressed, and create uneven revenue recognition across periods.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $2.94 and its highest was $9.94 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.30B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is in 64 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.047 by -$0.043.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.02.
How many shares outstanding does Alvotech have?
Alvotech has 312,048,280 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.047. Following the earnings report the stock price went down -10.364%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.67 (29.27% Upside)
$4.67 (29.27% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.62%
12-Months-Change
Fundamentals
Return on Equity
35.22%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$4.67
▲(29.27% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.54% Mutual Funds
1.59% Other Institutional Investors
96.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---